Reddit Posts
The Week Before: How News Impacted Stock Prices
ABOS: what’s everyone’s thoughts?
I shorted ABOS at 9.14 and 9.13.200 shares?
💰💰💰Good morning! #premarket #watchlist 09/28 $ABOS -Alzheimer buzz with BIIB, $LGVN -Alzheimer buzz with BIIB, $BIIB -Biogen Stock Soars On Promising Data From Late-Stage Alzheimer's Drug Trial, $SILO -possible offering in the end. S1 form active
💰💰💰Good morning! #premarket #watchlist 09/28 $ABOS -Alzheimer buzz with BIIB, $LGVN -Alzheimer buzz with BIIB, $BIIB -Biogen Stock Soars On Promising Data From Late-Stage Alzheimer's Drug Trial, $SILO -possible offering in the end. S1 form active
💰💰💰Good morning! #premarket #watchlist 09/28 $ABOS -Alzheimer buzz with BIIB, $LGVN -Alzheimer buzz with BIIB, $BIIB -Biogen Stock Soars On Promising Data From Late-Stage Alzheimer's Drug Trial, $SILO -possible offering in the end. S1 form active
Mentions
\-7.3% down this month, 22% up YTD, and 78% up since last June (when I first took stocks seriously). I used to take small positions in runners (e.g. IXHL, BTAI), but they were inconsistent and needed too much attention. Now I build big positions in stocks with legs (e.g. PLSR, SLS, ABOS, ASX:EOS, LSE:HUI). Had three losses. One (PLBY) was just daft; initial lateness made me hungry for bigger gains, so +20% turned into -5% (and dropping). A second (INTS) required risky dip-buying to return to profit. I took the profit percentage to buy more when it's diluted, but am determined to *never* leave that stock.
>He also said they did see improvement in social anxiety, about on par with existing treatments Normally this would ruin chances of FDA approval. However, ATAI's focus is on *treatment-resistant* depression and anxiety. So as long as its psychedelic pipeline works (and traditional SSRIs don't), it meets the required use case - and investors sell-off was overblown. I exited ATAI in early October but will trim both SLS and ABOS profits to buy back in.
ABOS rally seems to be caused by upward revision in the estimated size and CAGR of the US Alzheimer's drug market. That's fundamental, so it's a rare occasion I'll be buying into a rally.
PLSR is having a lil' dip. They've got new drilling underway, so any buy-the-rumour types might want to hop in here. RBW looks good too. Price has held up nicely as we enter crunch time for their Brazilian feasibility report. US interest in their South African partner may - *may* \- get their Burundi mine unlocked (one of the largest REE reserves in the world). ABOS is rising like SLS. I'm not entirely sure why, but suspect this is just how promising biotech pipelines behave when investors don't have to worry about their cash runway. If so, we aren't yet at the pre-data peak.
ABOS and ATAI. They're giving me good vibes
I really am quite a big fan of ABOS. Surprised it's going up. Maybe it can rally like SLS. Probably not. In any event, it's got a while to go before Phase 2 data.
Bought more with ABOS profits and a tiny SLS sale.
ABOS looks interesting. I think it's got further to fall from its present high (the catalyst last month was a single event), but it's behaving counter-intuitively - the price *rallied* after a trial extension, meaning either people in-the-know are confident about its lead drug's performance and/or the company's huge cash runway makes it a safer place to invest. Someone is also FUDding it hardcore. Coincident articles on Yahoo Finance, Saudi Exchange, Wall Street Zen, etc. raise concerns over things that are downright normal for pre-clinical biotechs, including lack of revenue (no shit), ongoing losses (the cash runway is enormous; grant options plentiful...), and insider stock sales which the articles admit are tax-related.
I personally like ABOS, RZLV, and IBRX.
I'm in on a few good and a few real bad... Good (or rather, hopeful)- ABOS, SLS, NFE. These have promising months ahead of them I think. Bad (or rather, riskier than I realized when I went in)- ROLR, THH. Both have potential, but low odds... I'm just holding bags so no point getting out of them
We still think ABOS is a buy at this point?
Thanks for the ABOS call, it’s running in AH and looks primed for a good week
Hey guys, ABOS is up 27% today... I wrote about it on Sunday afternoon for those who missed -- [https://www.reddit.com/r/pennystocks/comments/1qmy1yk/comment/o1v2xmo/](https://www.reddit.com/r/pennystocks/comments/1qmy1yk/comment/o1v2xmo/)
ABOS up 25% today! Price Target increased to $7
Folks, I'm working on scanner and I'd like to hear your opinion, what else could be done there: [https://pennypulse.co/](https://pennypulse.co/) it worked really well on **ABOS** today. what else do we want to see there?
ABOS -- 40% this morning on 10X times volume. I hope my followers didn't sleep on it!
ABOS -- 30% this morning on 5X times volume. I hope my followers didn't sleep on it!
Keep ABOS on your radar tomorrow morning -- it has real breakout potential.
Keep ABOS on your radar tomorrow morning -- it has real breakout potential.
ABOS and SGMO for this week
ABOS, NMRA and COSM for this week
Ive been in ABOS for 1000 shares since 1.42. My only concern is they are bleeding cash but they could hit gold and they just reported reduced costs for administering their antibodies.
I’m in $ADIL, $ABOS, and heavily in $CGTX
I am looking at $ABOS for the July 27th readout and $WINT for a potential play if $IXHL hits and the buy in still looks reasonable. I am also looking at $CGTX as a long play.
Any chance you have any DD on ABOS? Everything I am reading sounds good but I am an ape...
What day is this? You AI price prediction is -4.75% but last daily move was -2.8%. $ABOS a bit below was predicted of -1.8% but instead last change was -5%
Few months ago I scooped up 10,000 shares at .32 because somebody on the pennystock subReddit convinced me to. However, I also bought ABOS and RR because of somebody on the pennystock subReddit. I just wanna know who to sue (or simp for) when all is said and done. :)
Ok very quick research, company has 6 months left of cash, 3.7M, spending a cash burn of 1.8M per Q. So basically if you are spending 1.8M per Q you are: A) not developing any AI B) not developing anything. A clinical development process costs millions. Plus, its not even shorted, it wont squeeze, the data you are looking say nothing by itself, word of advice dont chase squeezes. Almost no one here understands how a squeeze really work. Share for shorting availability says nothing by itself, and actually in most cases a low availability signals it is not squeezable (if thats even a word) This IS financial advice: stay away from this one. If you want to check out some companies with potential Pennies: RBOT, QUBT, CYN, ARQQ, QBTS, CYBN, ABOS, RGTI Mid cap: PATH, PARA I recommend using DilutionTracker.com to check cash position on pennies before even doing more research. All Quantum stocks are getting a lot of interest, QUBT being the most bought, I bought it at 1 and the lowest was I believe .40 cents, closed yesterday above 4. Did an offering now so it will pull back considerably. This is NOT financial advice, just some examples of stocks I like and have positions, small in some and very large in others, do your own research.
I like Atos Clnn Goss Bcab ABOS Adap Tlry. If even half if those take off I'll be happy. So far so good. These are bumpy road long holds. ASTS looks like a crazy ride. Not a penny stock but acts like one. Already triple profit pulled so no biggie if it crashed out with the original investment i left in. But worth a look
GOSS, ABOS, CLNN,ATOS All mid to long plays with 4x to 10x potential, in my opinion do your own DD
That never means anything for efficacy necessarily especially in AD where at best you’re going for slowing of cognitive decline vs. placebo which takes a long time. Look at the Clarity-AD study which was actually a positive trial. SAVA patients are more likely simply tolerating the drug enough to roll over hence the high attrition rate. If anything extremely clean safety would make me think that trades with efficacy and ph3 will fail on the primary endpoint I’d look at ABOS or CGTX targeting the a-beta oligomers with oral drugs, those at least are far more externally validated than SAVA’s drug MOA, and trading far cheaper granted they are still in ph2. SAVA at a >$1B mkt cap is not an attractive risk/reward imo
NKLA and ABOS are my long plays. Both have been pretty beat down this past year and have tremendous upside. Of course, they could both go broke, so it’ll be interesting to see how it plays out. Best of luck to you and your picks.
That’s one strategy…another is just load up on stonks like ABOS while still near its ATL. 🦍
Why buy at 3.35 when you can buy at 2.55 #ABOS
What are yalls thoughts on $ABOS right now? Should I keep holding or cut my losses? (I’m down 17%)
$ABOS up almost 100% premarket wtf
$ABOS just starting with pre-market gains. Based on its past movement, after critical news releases, could see it blow past $10.
Symbol ABOS just release positive phase 1 data for Alzheimer’s disease. Primary and secondary endpoints were met. Monday morning will shoot up
ABOS limit order $6.20 at open, exit at $7 since their phase 1 study of ACU193 just published
Sava is the most useless Alz stock and a bunch of frauds. LLY has their ph3 data out in July 16-20 and will be approved. Dona probably do better than BIIB’s Leqembi in actual sales. PRTA and ABOS are companies targeting the same amyloid Beta pathway and could have more promise.
Who knows its a biotech. Some other biotechs to look at though are HOOK, KRON, ABOS, PLX
$ABOS there it is folks! The offering! https://stocktwits.com/Investment_Engineer/message/487823686
Omg, did I hurt your feelings? Bagholder angwy? :( And brother, ATV, PEPG, ABOS, PRTA, SOBR, a lot more in the past few days, but sure, throw your money into APRN and continue to "HODL" to $10 or whatever lmao. And lmfao, hope your advice works for you as much as mine works for me. I don't gotta hold any bags waiting for a turnaround or some "squeeze". I make my money and get out. Easy peeeeeeezy, kid.
Just saw this post as my alert went off that ABOS is above $9.50...
Short ABOS now.It is consolidating.Will trap lots of buyers